Microbiotica's $45M Boost: A New Era for IBD Treatment?

Jan de Vries · 2026-10-16

Microbiotica, a British biopharma company, just announced the first close of a €42 million ($45 million) Series C round. That's a big deal for a company developing precision microbiome medicines. But what does it mean for the future of inflammatory bowel disease (IBD) treatment? Let's break it down. ### The Financing: Who's Behind the Big Bet? The round was led by British Business Bank, with participation from Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, and Seventure Partners. All existing Series B investors joined in, showing strong confidence in Microbiotica's approach. Tim Sharpington, CEO of Microbiotica, said: "This financing marks an important next stage for Microbiotica and reflects the significant progress we have made in translating our powerful genomics-driven microbiome platform into clinical-stage products." He also highlighted the development of a scalable and cost-effective manufacturing process. ### What's Next for Microbiotica? The company is now focused on taking MB310, its lead candidate, into Phase 2 clinical development for ulcerative colitis. In a Phase 1b study, MB310 produced statistically significant clinical remission with no safety issues. That's promising news for the millions living with this chronic condition. Carmine Circelli, Senior Investment Director at British Business Bank, added: "We believe Microbiotica is emerging as a world leader in the development of microbiome therapeutics. This funding allows the Company to move MB310 forward into a Phase 2 trial which, if it confirms the promise seen in Phase 1b, has the potential to be a major breakthrough in the treatment of ulcerative colitis." ### The Bigger Picture: European Biotech Is Heating Up Microbiotica's raise comes amid a wave of European biotech investments in 2026. Here's a quick rundown: - Germany's mbiomics secured an additional €12 million ($13 million) for microbiome-based therapeutics, bringing its Series A to €30 million ($32 million). - UK-based OutPost Bio raised €2.9 million ($3.1 million) to expand its human microbiology modelling platform. - France's Bionyra Pharma secured €143 million ($154 million) to develop treatments for inflammatory diseases, including IBD. - Paris-based Generare raised €20 million ($21.5 million) for microbial-genome-based drug discovery. - London-based Alchemab Therapeutics received €29.3 million ($31.5 million) from British Business Bank to advance its clinical pipeline. Together, these announcements represent approximately €207.2 million ($223 million) in newly reported financing, rising to €249.2 million ($268 million) when Microbiotica's round is included. That's a lot of cash flowing into European biotech. ### How Microbiotica's Platform Works Founded in 2016 as a spin-out from the Wellcome Sanger Institute, Microbiotica has developed a genomics-driven microbiome platform. It combines a diverse microbiome culture collection, a proprietary human Reference Genome Database, advanced bioinformatics, and machine learning tools. When applied to clinical trial datasets, the platform can identify bacteria associated with favorable outcomes in specific patient populations. This precision approach could lead to more effective treatments for a range of diseases. Microbiotica has already established partnerships with MSD, Cancer Research UK, Genentech, The University of Adelaide, and Cambridge University Hospitals NHS Foundation Trust. These collaborations validate the company's science and open doors for future development. ### Why This Matters for IBD Patients Ulcerative colitis is a type of IBD that affects millions worldwide. Current treatments often involve trial and error, and many patients don't achieve lasting remission. A precision microbiome therapy like MB310 could change that by targeting the specific bacterial imbalances that drive the disease. Dr. Sam Williams, Venture Partner at IP Group, said: "We have been very impressed by Microbiotica's progress since we first invested in the Company. There is an important opportunity to advance Microbiotica's precision microbiome approach into a larger clinical study, and we are pleased to continue supporting the Company as it enters this next phase of development." ### The Road Ahead Phase 2 trials will be crucial. If MB310 confirms the promise seen in Phase 1b, it could become a major breakthrough in IBD treatment. And with the backing of strong investors and a proven platform, Microbiotica is well-positioned to make that happen. For now, all eyes are on the company as it takes this next step. If successful, it could not only transform treatment for ulcerative colitis but also pave the way for other microbiome-based therapies. That's something worth watching.